

Form PTO-1449  
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DCKET

960296.97745

SERIAL NO.

09/970,076

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Young/Bradley/Wellesley/Mogridge

FILING DATE:

10/03/2001

GROUP

1032 1645

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>mm</i>	✓	Beauregard, et al., "Anthrax Toxin Entry into Polarized Epithelial Cells," <u>Infection and Immunity</u> 67:3026-3030 (1999)
<i>mm</i>	✓	Boerger, et al., "Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types," <u>Proc. Natl. Acad. Sci. USA</u> 96:9867-9872 (1999)
<i>mm</i>	✓	Dickeson, et al., "Ligand recognition by the I domain-containing integrins," <u>Cell. Mol. Life Sci.</u> 54:556-566 (1998)
<i>mm</i>	✓	Elliott, Jennifer, "Assembly and Translocation of Anthrax Toxin," Ph.D. Thesis, Department of Microbiology (Cambridge, MA, Harvard University) pp. 35-65 (1998)
<i>mm</i>	✓	Escuyer, et al., "Anthrax Protective Antigen Interacts with a Specific Receptor on the Surface of CHO-K1 Cells," <u>Infection and Immunity</u> 59:3381-3386 (1991)
<i>mm</i>	✓	Genbank Accession Number AK001463, "Homo sapiens cDNA FLJ10601 fis, clone NT2RP2005000," <u>NCBI Sequence Viewer</u> 2 pages (9/28/2001)
<i>mm</i>	✓	Genbank Accession Number BC012074, "Homo sapiens, similar to tumor endothelial marker 8, clone MGC:19967 IMAGE:4563020, mRNA, complete cds," <u>NCBI Sequence Viewer</u> 2 pages (09/25/2001)
<i>mm</i>	✓	Genbank Accession Number NM_032208, "Homo sapiens tumor endothelial marker 8 (TEM8), mRNA," <u>NCBI Sequence Viewer</u> 3 pages (11/2/01)
<i>mm</i>	✓	Gordon, et al., "Inhibitors of Receptor-Mediated Endocytosis Block the Entry of <i>Bacillus anthracis</i> Adenylate Cyclase Toxin but Not That of <i>Bordetella pertussis</i> Adenylate Cyclase Toxin," <u>Infection and Immunity</u> 56:1066-1069 (1988)
<i>mm</i>	✓	Hanna, et al., "On the role of macrophages in anthrax," <u>Proc. Natl. Acad. Sci. USA</u> 90:10198-10201 (1993)
<i>mm</i>	✓	Hanna, P., "Anthrax Pathogenesis and Host Response," <u>Current Topics in Microbiology and Immunology</u> 225:13-35 (1998)
<i>mm</i>	✓	Klimpel, et al., "Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin," <u>Proc. Natl. Acad. Sci. USA</u> 89:10277-10281 (1992)
<i>mm</i>	✓	Lee, et al., "Crystal Structure of the A Domain from the $\alpha$ Subunit of Integrin CR3 (CD11b/CD18)," <u>Cell</u> 80:631-638 (1995)
<i>mm</i>	✓	Leppla, Stephan A., "The bifactorial <i>Bacillus anthracis</i> lethal and oedema toxins," <u>The Comprehensive Sourcebook of Bacterial Protein Toxins</u> Chapter 12:243-263 (1999)

EXAMINER

DATE CONSIDERED

8/29/02

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. QBMAD\328073

#8

RECEIVED

APR 03 2002

TECH CENTER  
1630/2900

Form PTO-1449  
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET

960296.97745

SERIAL NO.

09/970,076

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APR 01 2002

(Use several sheets if necessary)

APPLICANT(S): Young/Bradley/Wellesley/Mogridge

FILING DATE:

10/03/2001

GROUP

1632

## U.S. PATENT DOCUMENTS

* EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
								TECH CENTE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>mm</i>	✓	Menard, et al., "The vacuolar ATPase proton pump is required for the cytotoxicity of <i>Bacillus anthracis</i> lethal toxin," <u>FEBS Letters</u> 386:161-164 (1996)
<i>mm</i>	✓	Miller, et al., "Anthrax Protective Antigen: Prepore-to-Pore Conversion," <u>Biochemistry</u> 38:10432-10441 (1999)
<i>mm</i>	✓	Milne, et al., "Anthrax Protective Antigen Forms Oligomers during Intoxication of Mammalian Cells," <u>The Journal of Biological Chemistry</u> 269:20607-20612 (1994)
<i>mm</i>	✓	Petosa, et al., "Crystal structure of the anthrax toxin protective antigen," <u>Letters to Nature</u> 385:833-838 (1997)
<i>mm</i>	✓	Snitkovsky et al, "Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein," <u>Proc. Natl. Acad. Sci. USA</u> 96:7063-7068 (1998)
<i>mm</i>	✓	Snitkovsky, et al., "A TVA-Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor," <u>Journal of Virology</u> 74:9540-9545 (2000)
<i>mm</i>	✓	Snitkovsky, et al, "Targeting Avian Leukosis Virus Subgroup A Vectors by Using a TVA-VEGF Bridge Protein," <u>Journal of Virology</u> 75:1571-1575 (2001)
<i>mm</i>	✓	Croix, et al., "Genes Expressed in Human Tumor Endothelium," <u>Science</u> 289:1197-1202 (2000)
<i>mm</i>	✓	Zamore, Philip D., "RNA interference: listening to the sound of silence," <u>Nature Structural Biology</u> 8:746-750 (2001)

EXAMINER

DATE CONSIDERED

8/29/02

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. QBMA0328073

RECEIVED

APR 03 2002

TECH CENTER 100/2900